Non-small-cell lung cancer: how to manage EGFR-mutated disease

Federica Pecci, Luca Cantini, Giulio Metro, Biagio Ricciuti, Giuseppe Lamberti, Ammad Ahmad Farooqi, Rossana Berardi

Article Type

Review

Published

The authors provide an updated and comprehensive summary of the latest advancements in the quest for compounds targeting EGFR-mutant advanced non-small-cell lung cancer, discussing the biological rationale underlying the development of a forefront combination of TKI and/or new antibody–drug conjugates.

Read more

Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease

Giulio Metro, Andrea De Giglio, Biagio Ricciuti, Marco Siringo, Daniele Marinelli, Alain Gelibter, Federica Pecci, Rossana Berardi, Luca Cantini, Alessandro Di Federico, Elisa Andrini, Mirta Mosca, Giuseppe Lamberti, Marta Brambilla, Giannis Mountzios

Article Type

Review

Published

The authors provide a concise but comprehensive summary of the challenges that lie ahead as we move towards personalized treatment of Ex20ins-mutant and HER2-mutant advanced NSCLC, also suggesting a treatment algorithm that could be followed for patients with these genetic aberrations.

Read more

Non-small-cell lung cancer: how to manage RET-positive disease

Elisa Andrini, Mirta Mosca, Linda Galvani, Francesca Sperandi, Biagio Ricciuti, Giulio Metro, Giuseppe Lamberti

Article Type

Review

Published

This article reviews the biology, clinicopathological characteristics, targeted therapies and mechanisms of resistance of advanced non-small-cell lung cancer harbouring RET fusions to provide treatment guidance for these patients.

Read more

Advanced non-small-cell lung cancer: how to manage non-oncogene disease

Andrea De Giglio, Alessandro Di Federico, Chiara Deiana, Biagio Ricciuti, Marta Brambilla, Giulio Metro

Article Type

Review

Published

This article provides a review of the current treatment approaches to advanced non-small-cell lung cancer in patients without molecular driver alterations, with an additional focus on special populations, concomitant medications, and other considerations that might be useful for daily clinical practice.

Read more

Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant disease

Juan Bautista Blaquier, Gonzalo Recondo

Article Type

Review

Published

In this article, the authors focus on the management of patients with MET exon 14 skipping alterations by addressing the biology of the MET receptor and exon 14 skipping mutations, current treatment strategies, and sequential treatment options based on resistance mechanisms to MET inhibitors in patients with non-small-cell lung cancer.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.